Genesis Bioventures Announces Restructuring Management Agreement
News Nov 11, 2005
Experigen's founder, Douglas C. Lane, an executive with over 30 years experience in pharmaceutical, biotechnology, diagnostics and technology companies, will work closely with GBI's board of directors and officers to develop and execute the plan.
“Mr. Lane's management of business development and mergers and acquisitions at SmithKline Beecham (now GlaxoSmithKline), his interim board experience at Human Genome Sciences, the IPO development at Hyseq Corporation (now Nuvelo) and his recent leadership at the ViaSpace company, ViaLogy Corp., is an excellent fit with our breast cancer diagnostics company and our prion disease rapid assay company,” said Mr. McCartney, Chairman and CEO of Genesis Bioventures.
“We are very pleased to have Mr. Lane lead our growth initiatives.”
“Genesis Bioventures is an undiscovered company with unique growth opportunities,” Mr. Lane said.
“I am looking forward to working with Mr. McCartney, the board and management to create strong value for the Company and its shareholders.”
“There is an outstanding opportunity in GBI and its portfolio companies, with very good science and highly motivated and dedicated management and employees, all prerequisites to success.”
Hidden Signals in RNAs Regulate Protein SynthesisNews
Scientists have long known that RNA encodes instructions to make proteins. In a new study published in Nature, scientists describe how the protein-making machinery identifies alternative initiation sites from which to start protein synthesis.READ MORE
Mouse Study Suggests That Dietary Fat, Not Carbs, Drives ObesityNews
A mouse study that made over 100,000 measurements of body weight and fat has concluded that the sole driver of obesity in mice is increased dietary fat content.READ MORE